2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14989R
    SQ109 (Standard) 502487-67-4 98%
    SQ109 (Standard) is the analytical standard of SQ109. This product is intended for research and analytical applications. SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for cell killing of 50±8 nM. SQ109, targets MmpL3, is an antitubercular agent.
    SQ109 (Standard)
  • HY-149900
    Antiviral agent 33 2982270-24-4 98%
    Antiviral agent 33 (compound 1c) is a double-stranded DNA (dsDNA) virus inhibitor with IC50 values of 0.0790 and 0.1572 µM for VACV and AdV5, respectively. Antiviral agent 33 also has potential for oral administration.
    Antiviral agent 33
  • HY-14990A
    Sudoterb hydrochloride 1044503-04-9 98%
    Sudoterb (LL 3858) hydrochloride is an orally active anti-Tuberculosis agent.
    Sudoterb hydrochloride
  • HY-149919
    Antimalarial agent 23 98%
    Antimalarial agent 23 is an antimalarial benzimidazole with IC50s of 0.08 μM and 0.10 μM for PfNF54 and PfK1, respectively. Antimalarial agent 23 has potent β-hematin inhibition activity. Antimalarial agent 23 does not directly inhibit the conversion of heme to hemozoin.
    Antimalarial agent 23
  • HY-149925
    DNA Gyrase-IN-6 3034242-80-0 98%
    Antibacterial agent 138 is a benzothiazole inhibitor of bacterial DNA gyrase and topoisomerase IV. Antibacterial agent 138 exhibits favorable solubility and plasma protein binding. Antibacterial agent 138 has antibacterial activity against Gram-positive and Gram-negative strains. Antibacterial agent 138 is a dual GyrB and ParE inhibitor.
    DNA Gyrase-IN-6
  • HY-149928
    NNRT-IN-1 2925364-09-4 98%
    NNRT-IN-1 (compound 8r) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor featuring significantly anti-resistance efficacy. NNRT-IN-1 inhibits the wild-type HIV-1 and five mutant strains with EC50s in the nanomolar range. NNRT-IN-1 displays favorable pharmacokinetic properties.
    NNRT-IN-1
  • HY-149929
    EBL-3183 2872672-18-7 98%
    EBL-3183, an indole-2-carboxylate, is a potent metallo-β-lactamase (MBL) inhibitor. EBL-3183 is reversibly binding, non-covalent, competitive NDM-1 inhibitor with a pIC50 of 7.7.
    EBL-3183
  • HY-149936
    HIV-1 protease-IN-8 2925287-55-2 98%
    HIV-1 protease-IN-8 (compound 34b) is a potent HIV-1 protease inhibitor with an IC50 value of 0.32 nM. HIV-1 protease-IN-8 displays IC50s of 0.29 μM and 1.90 μM for wild-type HIV-1 (HIV-1NL4-3) and drug-resistant variant (HIV-1MDR), respectively. HIV-1 protease-IN-8 displays robust antiviral activity against both wild-type HIV-1 and drug-resistant variant.
    HIV-1 protease-IN-8
  • HY-149937
    Antimalarial agent 24 2299199-54-3 98%
    Antimalarial agent 24 (Compound 7) is an antimalarial agent in vitro. Antimalarial agent 24 inhibits P. falciparum W2 strain with an IC50 of 0.81 μM. Antimalarial agent 24 displays a CC50 higher than 200 μM against HepG2 cells.
    Antimalarial agent 24
  • HY-149938
    Antimalarial agent 25 2944456-41-9 98%
    Antimalarial agent 25 is an orally active 1,4-naphthoquinones derivative with antimalarial activity. Antimalarial agent 25 shows cytotoxicity against P. falciparum. Antimalarial agent 25 inhibits P. burghei induced parasitemia in vivo.
    Antimalarial agent 25
  • HY-149939
    Antimalarial agent 26 2299199-56-5 98%
    Antimalarial agent 26 is an orally active 1,4-naphthoquinones derivative with antimalarial activities. Antimalarial agent 26 shows cytotoxicity against P. falciparum and selectivity over mammalian cell lines. Antimalarial agent 26 inhibits P. burghei induced parasitemia in vivo.
    Antimalarial agent 26
  • HY-149940
    SIMR3030 2708270-99-7 98%
    SIMR3030 is a potent SARS-CoV-2 PLpro inhibitor with an IC50 value of 0.0399 µg/mL. SIMR3030 shows antiviral activity. SIMR3030 decreases SARS-CoV spike, ORF1b, IFN-α, IL-6 mRNA expression. SIMR3030 exhibits a satisfactory safety profile in mice.
    SIMR3030
  • HY-149955
    SARS-CoV-2-IN-38 2882823-27-8 98%
    SARS-CoV-2-IN-38 (compound 24) is a SARS-CoV-2 inhibitor with good oral bioavailability in mice (F%=39.75%).
    SARS-CoV-2-IN-38
  • HY-149956
    Antileishmanial agent-15 2934738-38-0 98%
    Antileishmanial agent-15 (compound 13c) is a potent antileishmanial agent. Antileishmanial agent-15 shows antileishmanial and cytotoxic activity against L. major promastigotes and amastigotes, with IC50 values of 0.78 and 0.99 μM, respectively.
    Antileishmanial agent-15
  • HY-149957
    Antileishmanial agent-16 2934738-41-5 98%
    Antileishmanial agent-16 (compound 14c) is an anti-Leishmania agent. Antileishmanial agent-16 has superior anti-Leishmania major promastigotes activity (IC50 = 0.59 µM) and anti-Leishmania major amastigotes activity (IC50 = 0.81 µM). Antileishmanial agent-16 has good safety to mammalian cells (VERO cells).
    Antileishmanial agent-16
  • HY-149958
    Antileishmanial agent-17 2934738-40-4 98%
    Antileishmanial agent-17 is a coumarin hybrid compound with antileishmanial effects (IC50 <0.78 μM). Antileishmanial agent-17 is safe to normal VERO cells. Antileishmanial agent-17 binds to folate pathway enzymes pteridine reductase and DHFR-TS. And Antileishmanial agent-17 shows the most potent with IC50 value of 0.40 μM against promastigote and 0.68 μM against amastigote, respectivley.
    Antileishmanial agent-17
  • HY-149960
    Antiparasitic agent-17 3043821-43-5 98%
    Antiparasitic agent-17 (compound 5u) is an orally active antiparasitic agent. Antiparasitic agent-17 inhibits Chloroquine sensitive (Pf3D7) and Chloroquine resistant (PfK1) strain with IC50s of 0.96 μM and 1.67 μM, respectively.
    Antiparasitic agent-17
  • HY-149961
    Anti-inflammatory agent 40 3043821-37-7 98%
    Anti-inflammatory agent 40 is a potential and orally active anti-malarial and anti-inflammatory agent. Anti-inflammatory agent 40 inhibits carrageenan induced paw swelling in vivo.
    Anti-inflammatory agent 40
  • HY-149980
    DCN-83 98%
    DCN-83, an anti-leishmania agent, is most potent against the amastigote form with an IC50 of 0.71 μM. DCN-83 has the potential to cross the blood-brain barrier and central nervous system.
    DCN-83
  • HY-149983
    Antibacterial agent 141 2930013-56-0 98%
    Antibacterial agent 141 (Compound B14) has antibacterial activity against four plant pathogens Xoo, Xac, Psa and Cmm, with an EC50 value of 1.28 μM. Antibacterial agent 141 can inhibit the formation of cell membrane and change cell permeability.
    Antibacterial agent 141
Cat. No. Product Name / Synonyms Application Reactivity